Nihon Jinzo Gakkai shi · 2008
[Combined effect of cyclosporin and prednisolone for minimal change nephrotic syndrome: comparison with prednisolone therapy].
Клинический случайСравнительное исследованиеАннотация на английскомСтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Hayashi Masanori, Kimura Noriyo, Fukatsu Atsushi
Аннотация
BACKGROUND: Minimal change nephrotic syndrome (MCNS) is the most common type of glomerular disease and treated mainly with corticosteroids, usually prednisolone(PSL). The recurrence rate during PSL treatment is approximately 20-30 %. In addition, the adverse effects of long term PSL treatment include diabetes, osteoporosis, infection etc, most of which are serious. We treated MCNS with PSL and cyclosporin (CyA) as an initial therapy to reduce PSL dosage and its side effects, and compared various clinical parameters in MCNS treated with the conventional PSL therapy.
SUBJECTS AND METHODS: MCNS patients were divided to two groups. Group A consisted of 10 patients, average age 40 years old, treated initially with PSL 20 mg and CyA (2 mg/kg B.W.). Group B consisted 15 patients, average age 43 years old, treated PSL, initial dose 34.7+/-11.9 mg. Data evaluated included whole admission term, reduction of body weight at the discharge, total PSL dosage, period of urinary protein excretion more than 1.0 g/day and side effects.
RESULTS: Average admission term was significantly shorter in Group A(19.3+/-8.8 days) than in Group B (56.5+/-22.3 days) (p= 0.0008). Reduction of body weight at discharge from admission was comparable in both Groups (A: 8.3+/-4.8 kg, B: 7.8+/-5.8 kg, p=0.8388). Total PSL dosage in Group A in hospital (386+/-173 mg) was smaller than in Group B (1,884+/-1,573 mg) (p=0.0067). PSL dosage out hospital for 6 months showed the same results A: 1,926+/-776 mg, B: 15,474+/-3,863 mg (p<0.0001). Periods with urinary protein excretion more than 1.0 g/day was slightly shorter in Group A (12.9+/-8.4 days) than Group B (23.7+/-18.3 days) (p= 0.0963).
SIDE EFFECTS: One patient in Group B had steroid induced diabetes. Other patients did not show significant side effects. RECURRENCE: Two patients in Group A had recurrence after CyA stopped, but were improved by treatment.
CONCLUSION: Initial therapy with PSL and CyA for MCNS is effective for the resolution of nephrotic syndrome, the reduction of PSL amount and whole admission term.
SUBJECTS AND METHODS: MCNS patients were divided to two groups. Group A consisted of 10 patients, average age 40 years old, treated initially with PSL 20 mg and CyA (2 mg/kg B.W.). Group B consisted 15 patients, average age 43 years old, treated PSL, initial dose 34.7+/-11.9 mg. Data evaluated included whole admission term, reduction of body weight at the discharge, total PSL dosage, period of urinary protein excretion more than 1.0 g/day and side effects.
RESULTS: Average admission term was significantly shorter in Group A(19.3+/-8.8 days) than in Group B (56.5+/-22.3 days) (p= 0.0008). Reduction of body weight at discharge from admission was comparable in both Groups (A: 8.3+/-4.8 kg, B: 7.8+/-5.8 kg, p=0.8388). Total PSL dosage in Group A in hospital (386+/-173 mg) was smaller than in Group B (1,884+/-1,573 mg) (p=0.0067). PSL dosage out hospital for 6 months showed the same results A: 1,926+/-776 mg, B: 15,474+/-3,863 mg (p<0.0001). Periods with urinary protein excretion more than 1.0 g/day was slightly shorter in Group A (12.9+/-8.4 days) than Group B (23.7+/-18.3 days) (p= 0.0963).
SIDE EFFECTS: One patient in Group B had steroid induced diabetes. Other patients did not show significant side effects. RECURRENCE: Two patients in Group A had recurrence after CyA stopped, but were improved by treatment.
CONCLUSION: Initial therapy with PSL and CyA for MCNS is effective for the resolution of nephrotic syndrome, the reduction of PSL amount and whole admission term.